ClinicalTrials.gg
RecruitingNCT04063592Updated Jul 9, 2026

AMI Construction in Lower Extremity Residual Limbs

An interventional study of Residual limb revision in Amputation, sponsored by Brigham and Women's Hospital. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will involve the development of a novel approach to lower extremity residual limb surgical revision that offers the promise of augmenting volitional motor control, restore proprioception and reverse atrophy

Read the detailed description

The hypothesis of this research protocol is that we will be able to modify the residual limbs of patients who have already undergone lower extremity amputations so as to include biological actuators that will enable the successful employment of next generation lower extremity prostheses, diminish/eliminate phantom limb pain, restore proprioception and regenerate lost muscle mass. The specific aims of the project are as follows:

  1. To develop a standardized operative technique for both above knee (AK) and below knee (BK) amputation revision procedures that includes AMIs to restore musculotendinous proprioceptive capabilities
  2. To assess the capacity for these actuators to provide enhanced motor control and sensory feedback, as well as ablate phantom limb symptomatology and augment residual limb muscle mass
  3. To determine the reinnervation time course and longevity of these biological constructs
  4. To validate the functional and somatosensory superiority of the proposed revision technique over standard approaches to BKA and AKA
  5. To develop a modified acute postoperative rehabilitation strategy suited to this new surgical approach
02

Conditions studied

  • Amputation

Browse trials for

Keywords

  • Amputation
  • Residual limb pain
  • Phantom pain
  • Residual limb atrophy
  • Prosthesis control
03

In context

Phantom Limb

163 studies on the registry are indexed under Phantom Limb; 35 are open to participants now.

This study's planned enrollment of 26 is below the median of 30 across 125 interventional studies indexed under Phantom Limb.

Browse Phantom Limb studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,267 studies on the registry; 228 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages of 18-65
  • Has already undergone a standard AKA or BKA procedure
  • Suffers from symptoms such as:

    • Intractable pain
    • Deterioration of skin on or around stump
    • Suffering from other sources of discomfort arising from stump
  • Intact inherent wound healing
  • Adequate communication skills
  • High motivation

Exclusion criteria

Exclusion Criteria:

  • Inadequate health to undergo operative procedure using standard anesthesia (i.e. cardiopulmonary)
  • Individuals with impaired wound healing
  • Individuals suffering from extensive peripheral neuropathies
  • Active smokers
  • Individuals with a history of poor compliance
  • Women who are pregnant or plan to become pregnant before surgical intervention
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Intervention

    Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures

    Procedure: Residual limb revision

Interventions

  • ProcedureResidual limb revision

    Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)

06

What researchers measure

Primary outcomes

  1. Limb Morphology and Changes in Muscle Volume

    Clinical examination and images from CT/MRI will be combined to construct a holistic view of the morphology of the residual limb. Imaging studies and limb measurements taken in clinic will also be used to measure muscle atrophy/hypertrophy over time.

    Time frame: Years 1-3

  2. Degree of Motor Activation of AMI Muscles and Volitional Control of Phantom Limb

    Clinical examination will confirm the sliding motion of the AMI constructs with radiologic evaluation measuring the length of muscle excursion through each construct. Functional testing and testing using a prosthesis will determine how well a patient is able to volitionally control the AMI muscles.

    Time frame: Years 1-3

  3. Evidence of Proprioception

    Subjective reporting combined with tests run using a prosthesis will indicate if proprioception is still intact after surgery. Results will be confirmed by monitoring brain activity during limb movement activities via fMRI.

    Time frame: Years 1-3

  4. Evidence of Sensory Perception

    Subjective reporting and clinical tests of Semmes-Weinstein and two-point discrimination will determine if the patient has sensory perception on the residual limb.

    Time frame: Years 1-3

  5. General Health

    Patient-reported outcomes metrics from five validated tests (SIP136, EQ-5D, SF-36, LEFS, PROMIS) will be combined to create an overall picture of patients' general health during and after their recovery.

    Time frame: Years 1-3

  6. Complications

    Delayed wound healing, infection, need for additional surgery, PE/DVT, death

    Time frame: Years 1-3

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be available to other researchers

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04063592
Collaborators
Massachusetts Institute of Technology
Responsible party
Matthew Carty (Principal Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Aug 21, 2019
Start date
Feb 24, 2020
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jul 9, 2026

Study contacts

Matthew J Carty, MD
Contact
mcarty@partners.org
6179834555
Research Coordinators
Contact
limbrestoration@bwh.harvard.edu
Matthew J Carty, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion